For this Article, imec’s Peter Peumans (CTO), Natalie Caspari (Senior Business Development Manager, Health & Life Sciences) and Maarten De Groof (Editor), explore the outcomes of a roundtable hosted at Advanced Therapies Week 2023, whereby the application of deep tech to cell and gene therapy development was discussed by industry experts.

Thanks to the emergence of advanced personalized therapies such as CAR-T cell therapies, diseases such as cancer will increasingly become curable rather than a death sentence. However, much work remains to be done. Since the process is
the product, it is only logical that the development and manufacturing process of cell and gene therapies (CGT) needs to move from a black-box approach towards a quality-controlled, measurable and efficient drug manufacturing procedure that has the desired effect on the patient.

To find out more, download the full article below or check out imec’s White Paper on ‘Raising the Bar in Manufacturing Cell Therapy Products’ >>

This Article has been produced in partnership with imec.